REGENXBIO Inc. (NASDAQ:RGNX) Corporate Logo

It was showed a decrease on Regenxbio Inc (NASDAQ:RGNX)’s short interest with 11.37%. FINRA published in February RGNX’s total 2.17 million short interest. That’s 11.37% down from 2.45 million shares. Former RGNX’s position will need 5 days to recover. It has 468,300 average volume. 7.8% is Regenxbio Inc float short.

RGNX hit $48.13 during the last trading session after $1.66 change.REGENXBIO Inc. has volume of 395,883 shares. Since February 16, 2018 RGNX has risen 75.68% and is uptrending. RGNX outperformed the S&P 500 by 75.68%.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.The firm is valued at $1.73 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.20.95 is the P/E ratio. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

For more REGENXBIO Inc. (NASDAQ:RGNX) news brought out briefly go to: Nasdaq.com, Seekingalpha.com, Benzinga.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Implied Volatility Surging for REGENXBIO (RGNX) Stock Options – Nasdaq” brought out on September 20, 2018, “REGENXBIO up 8% on new pipeline candidate for Batten disease – Seeking Alpha” on August 30, 2018, “32 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” with a publish date: February 05, 2019, “Chardan defends Regenxbio after bearish commentary; shares up 4% – Seeking Alpha” and the last “REGENXBIO’s RGX-181 nabs Rare Pediatric Disease tag for pediatric brain disorder – Seeking Alpha” with publication date: January 31, 2019.

REGENXBIO Inc. (NASDAQ:RGNX) Analyst Ratings Chart


Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.




Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *